Results 241 to 250 of about 77,108 (288)

Pharmacovigilance Insights Into Immune Checkpoint Inhibitor-Induced Risk of Paraneoplastic Syndrome: A Large-Scale Real World Study. [PDF]

CNS Neurosci Ther
Tang B, Song X, Sun Y, Wan J, Hu W, Ma Y, Lin Y, Zhang J, Wang Y, Feng H, Luo P, Guo D, Qu X.   +12 more
europepmc   +1 more source

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nature Medicine, 2022
Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of ...
Nazli Dizman, Luis Meza, Tanya B Dorff
exaly   +2 more sources

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Nature, 2022
Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma1–4.
Kohei Shitara, Jaffer A Ajani, Lucjan S Wyrwicz   +2 more
exaly   +2 more sources

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Nature Medicine, 2021
Tina Cascone, William N William, Annikka Weissferdt   +2 more
exaly   +2 more sources